Table 3 Results of clinical trials by genotyping modality
Study Location | Treatment Arm | Genotyping-corrected 42-day Risk of Treatment Failure, % (95% CI) | Risk Difference, Gel vs. CE, % (p value) | |
|---|---|---|---|---|
| Â | Â | Gel | CE | Â |
Kanungu | AL | 6.9 (3.8-12.1) | 5.5 (2.9-10.3) | 1.4 (0.4) |
| Â | DP | 2.4 (1.0-5.7) | 2.9 (1.3-6.3) | -0.5 (0.5) |
Risk Difference, AL vs. DP, % (p value) | 4.5 (0.07) | 2.6 (0.3) | Â | |
Apac | AL | 17.0 (11.8-24.0) | 10.7 (6.6-17.1) | 6.3 (0.02) |
| Â | DP | 8.5 (5.2-13.7) | 3.4 (1.5-7.4) | 5.1 (0.03) |
Risk Difference, AL vs. DP, % (p value) | 8.5 (0.03) | 7.3 (0.02) | Â | |